Elderly patients with Ph+ chronic myelogenous leukemia (CML)

Results of imatinib mesylate treatment

Latagliata Roberto, Breccia Massimo, Carmosino Ida, Sarlo Chiara, Montefusco Enrico, Mancini Marco, Chistolini Antonio, De Cuia Rosa, Russo Eleonora, Morano Salvatore Giacomo, Biondo Francesca, Spadea Antonio, Mandelli Franco, Alimena Giuliana, Natalino Fiammetta

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by all patients; seventeen patients (70.8%) attained a complete cytogenetic response (CCR), one (4.1%) attained a partial CR, one (4.1%) a minor CR (Ph+ 70%) and five (21%) were resistant (Ph+ 100%), toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and 23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3 months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7%) achieved CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients.

Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalLeukemia Research
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Cytogenetics
Imatinib Mesylate
Transcription Factor AP-1
Edema
Sepsis

Keywords

  • CML
  • Elderly
  • Imatinib

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Roberto, L., Massimo, B., Ida, C., Chiara, S., Enrico, M., Marco, M., ... Fiammetta, N. (2005). Elderly patients with Ph+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment. Leukemia Research, 29(3), 287-291. https://doi.org/10.1016/j.leukres.2004.08.002

Elderly patients with Ph+ chronic myelogenous leukemia (CML) : Results of imatinib mesylate treatment. / Roberto, Latagliata; Massimo, Breccia; Ida, Carmosino; Chiara, Sarlo; Enrico, Montefusco; Marco, Mancini; Antonio, Chistolini; Rosa, De Cuia; Eleonora, Russo; Giacomo, Morano Salvatore; Francesca, Biondo; Antonio, Spadea; Franco, Mandelli; Giuliana, Alimena; Fiammetta, Natalino.

In: Leukemia Research, Vol. 29, No. 3, 03.2005, p. 287-291.

Research output: Contribution to journalArticle

Roberto, L, Massimo, B, Ida, C, Chiara, S, Enrico, M, Marco, M, Antonio, C, Rosa, DC, Eleonora, R, Giacomo, MS, Francesca, B, Antonio, S, Franco, M, Giuliana, A & Fiammetta, N 2005, 'Elderly patients with Ph+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment', Leukemia Research, vol. 29, no. 3, pp. 287-291. https://doi.org/10.1016/j.leukres.2004.08.002
Roberto, Latagliata ; Massimo, Breccia ; Ida, Carmosino ; Chiara, Sarlo ; Enrico, Montefusco ; Marco, Mancini ; Antonio, Chistolini ; Rosa, De Cuia ; Eleonora, Russo ; Giacomo, Morano Salvatore ; Francesca, Biondo ; Antonio, Spadea ; Franco, Mandelli ; Giuliana, Alimena ; Fiammetta, Natalino. / Elderly patients with Ph+ chronic myelogenous leukemia (CML) : Results of imatinib mesylate treatment. In: Leukemia Research. 2005 ; Vol. 29, No. 3. pp. 287-291.
@article{60274680edc8434e8a6994c17f51ac70,
title = "Elderly patients with Ph+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment",
abstract = "Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by all patients; seventeen patients (70.8{\%}) attained a complete cytogenetic response (CCR), one (4.1{\%}) attained a partial CR, one (4.1{\%}) a minor CR (Ph+ 70{\%}) and five (21{\%}) were resistant (Ph+ 100{\%}), toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and 23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3 months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7{\%}) achieved CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients.",
keywords = "CML, Elderly, Imatinib",
author = "Latagliata Roberto and Breccia Massimo and Carmosino Ida and Sarlo Chiara and Montefusco Enrico and Mancini Marco and Chistolini Antonio and Rosa, {De Cuia} and Russo Eleonora and Giacomo, {Morano Salvatore} and Biondo Francesca and Spadea Antonio and Mandelli Franco and Alimena Giuliana and Natalino Fiammetta",
year = "2005",
month = "3",
doi = "10.1016/j.leukres.2004.08.002",
language = "English",
volume = "29",
pages = "287--291",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Elderly patients with Ph+ chronic myelogenous leukemia (CML)

T2 - Results of imatinib mesylate treatment

AU - Roberto, Latagliata

AU - Massimo, Breccia

AU - Ida, Carmosino

AU - Chiara, Sarlo

AU - Enrico, Montefusco

AU - Marco, Mancini

AU - Antonio, Chistolini

AU - Rosa, De Cuia

AU - Eleonora, Russo

AU - Giacomo, Morano Salvatore

AU - Francesca, Biondo

AU - Antonio, Spadea

AU - Franco, Mandelli

AU - Giuliana, Alimena

AU - Fiammetta, Natalino

PY - 2005/3

Y1 - 2005/3

N2 - Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by all patients; seventeen patients (70.8%) attained a complete cytogenetic response (CCR), one (4.1%) attained a partial CR, one (4.1%) a minor CR (Ph+ 70%) and five (21%) were resistant (Ph+ 100%), toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and 23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3 months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7%) achieved CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients.

AB - Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by all patients; seventeen patients (70.8%) attained a complete cytogenetic response (CCR), one (4.1%) attained a partial CR, one (4.1%) a minor CR (Ph+ 70%) and five (21%) were resistant (Ph+ 100%), toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and 23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3 months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7%) achieved CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients.

KW - CML

KW - Elderly

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=19944432935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944432935&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2004.08.002

DO - 10.1016/j.leukres.2004.08.002

M3 - Article

VL - 29

SP - 287

EP - 291

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -